RE:Tesamorelin article in Contagion Journal 1st
Thanks for your link:
"
In 2010, the FDA approved tesamorelin for use in people with HIV who suffer from lipodystrophy, and Grinspoon would like to see it prescribed more widely. “Certainly, it’s now even more compelling to use this drug in HIV patients with significant abdominal fat accumulation, many of who[m] are likely to have liver fat, which we now show to be reduced,” he said. “So, [there are] 2 benefits. We are working on larger studies to confirm our findings but the results are compelling and robust, and very exciting.”
Co-author Colleen Hadigan, MD, MPH, senior research physician at the National Institutes of Allergy and Infectious Diseases’ Laboratory of Immunoregulation, part of the NIH, agreed. “I think that this opens up an opportunity to rethink prescribing practices,” she told Contagion®, emphasizing that there’s no need for physicians to test for fatty liver in a patient who has HIV and abdominal fat before recommending tesamorelin. “This could be another piece of clinical information to justify adding another medication.”